ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO514

Characteristics and Prediction of Tumor Recurrence in Patients with Pheochromocytoma and Paraganglioma: A Single-Center Experience in Taiwan

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical


  • Tu, Yi-Ran, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan
  • Tu, Kun-Hua, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan

Both pheochromocytoma and paraganglioma are rare catecholamine-producing neuroendocrine tumors. Surgical resection is the only curative treatment for these tumors. Patients receiving tumor resections, however, still probably encountered tumor recurrence. To our best knowledge, it's still with unclear clinical presentation of these catecholamine-producing tumor and lack of useful parameters to predict recurrence after tumor resection. The aim of this study is to find predictors of tumor recurrence in patients with these two rare neuroendocrine tumors.


This study was conducted at a tertiary medical center in Taiwan retrospectively. Data collection by chart review was undertaken in a 2000-bed private university hospital in Taiwan between January 2000 and December 2021. In total, 310 patients with pathologic diagnosis of pheochromocytoma or paraganglioma were enrolled.


The study subjects were grouped as PCC and PGL and then further classified to sympathetic PPGLs and parasympathetic PPGLs according to the tumor origin. This study include 156 patients of PCC and 154 patients of PGL which larger tumor size, more symptoms of headache, arrythmia, diaphoresis, anxiety, and mass effects, more comorbidity of hypertension and hyperglycemia, higher urine epinephrine level, and higher renin level were significantly noted in patients with PCC. The other classification of the subjects including 247 patients with sympathetic PPGLs and 63 patients with parasympathetic PPGLs who have significant larger size of tumor, more symptoms of arrythmia, diaphoresis, body weight loss, and chest tightness without ischemic heart disease, and more comorbidity of hypertension and hyperglycemia in the group to sympathetic PPGLs. Of the subjects, there are 14 patients categorized as the recurrent group, and 289 patients categorized as non-recurrent group. Comparing with non-recurrent group, recurrent group are younger (p=0.03407), and have more genetic ancestry (p=0.02062).


Our study demonstrates the characteristics of PCC and PGL and several clinical parameters such as age and genetic ancestry are associated with tumor recurrence after tumor resection in patients with PCC or PGL. It will help clinician to closely monitor disease status after tumor resection.